Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | MSI-H status in advanced G/GEJ

Kohei Shitara • 28 Sep 2019
ESMO 2019
Gastrointestinal Cancer

Kohei Shitara, MD, National Cancer Center Hospital, Kashiwa, Japan, outlines the importance of microsatellite instability-high (MSI-H) status in the treatment of patients with advanced gastric and gastroesophageal junction cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Kohei Shitara

3:34
FLOW + SPOTLIGHT: addressing nausea + vomiting in gastric cancer treatment with 1L zolbetuximab
Kohei Shitara • 19 Jan 2024
2:26
NIVO + chemo vs chemo as 1L treatment for advanced GC/GEJC/EAC: 4 year yr follow-up of CheckMate 649
Kohei Shitara • 19 Jan 2024
2:59
The future of gastric cancer treatment beyond ESMO 2023
Kohei Shitara • 21 Oct 2023
4:14
KEYNOTE-585: perioperative pembrolizumab in stomach cancers
Kohei Shitara • 21 Oct 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals